Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy

HIGHLIGHTS

• who: Catarina Correia from the Through the application of the sixteen research questions, we identified , records, of which were duplicatesAfter reading the abstracts, we excluded , records. Finally, after fully reading all the records, we excluded , records for not having relevant information, resulting in , records being included in the systematic literature review (Fig., ). Citalopram's research question was the one that showed the most results, followed by venlafaxine. On the other hand, the research questions for moclobemide, reboxetine, and vortioxetine did not show any results (Table, ). The United States of America was the country with the most publications . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.